TECHNETIUM TC 99M SULFUR COLLOID
drug drugOn this page
Also known as 99mtc-labeled sulfur colloidAn-sulfur colloidAn-sulfur colloid kitTc99m-sulfur colloidTechnecollTechnescan sulfur colloidTechnetium (99mtc) sulfur colloidTechnetium tc 99m tscTechnetium tc-99m sulfur colloidTechnetium tc-99m sulfur colloid kitTesuloid
Summary
Technetium Tc 99M Sulfur Colloid (CHEMBL1201529) is an approved unknown (ATC V09DB05); indicated across 7 conditions including melanoma and breast carcinoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: V09DB05
- Indications: 7 conditions
- Clinical trials: 18
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201529 |
| Name | TECHNETIUM TC 99M SULFUR COLLOID |
| Type | Unknown |
| Max phase | 4 |
| ATC | V09DB05 |
Also known as: 99mtc-labeled sulfur colloid, An-sulfur colloid, An-sulfur colloid kit, Tc99m-sulfur colloid, Technecoll, Technescan sulfur colloid, Technetium (99mtc) sulfur colloid, Technetium tc 99m sulfur colloid, Technetium tc 99m tsc, Technetium tc-99m sulfur colloid, Technetium tc-99m sulfur colloid kit, Tesuloid
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| melanoma | 4 | MONDO:0005105 | EFO:0000756 |
| breast carcinoma | 4 | MONDO:0004989 | EFO:0000305 |
| breast neoplasm | 4 | MONDO:0021100 | MONDO:0007254 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| sebaceous adenocarcinoma | 2 | MONDO:0006962 | EFO:1001171 |
| cystic fibrosis | 1 | MONDO:0009061 | MONDO:0009061 |
Clinical trials
Total trials: 18.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE2 | 5 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07121595 | PHASE2 | RECRUITING | Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial |
| NCT00832429 | PHASE2 | COMPLETED | Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid |
| NCT01276054 | PHASE2 | TERMINATED | Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients. |
| NCT01642511 | PHASE2 | COMPLETED | Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative |
| NCT02294565 | PHASE1/PHASE2 | UNKNOWN | VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer |
| NCT02773238 | PHASE2 | COMPLETED | FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging |
| NCT00743314 | EARLY_PHASE1 | COMPLETED | Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer |
| NCT00003654 | Not specified | TERMINATED | Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer |
| NCT00005640 | Not specified | COMPLETED | Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer |
| NCT00012168 | Not specified | COMPLETED | Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat |
| NCT00042926 | Not specified | COMPLETED | Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer |
| NCT00052676 | Not specified | COMPLETED | Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer |
| NCT00070317 | Not specified | TERMINATED | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer |
| NCT00080860 | Not specified | COMPLETED | Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer |
| NCT00438477 | Not specified | COMPLETED | Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer |
| NCT00450723 | Not specified | COMPLETED | Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer |
| NCT02419807 | Not specified | COMPLETED | Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer |
| NCT02881554 | Not specified | TERMINATED | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: melanoma, breast carcinoma, breast neoplasm, neoplasm
- In clinical trials for: non-small cell lung carcinoma